Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the southwest oncology group

Christopher W. Ryan, Bryan H. Goldman, Primo N. Lara, Philip C. Mack, Tomasz M. Beer, Catherine M. Tangen, Dianne Lemmon, Chong Xian Pan, Harry A. Drabkin, E. David Crawford

    Research output: Contribution to journalArticlepeer-review

    146 Scopus citations

    Fingerprint Dive into the research topics of 'Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the southwest oncology group'. Together they form a unique fingerprint.

    Medicine & Life Sciences